Boeing secures $883 million Army contract for cargo support services
In a turbulent market environment, shares of Eleven Biotherapeutics (CARM) have reached a 52-week low, dipping to $0.2. According to InvestingPro data, the stock’s RSI indicates oversold territory, while analysts maintain a $1 price target, suggesting potential upside. This significant downturn reflects a broader trend for the biotech firm, which has seen its stock value plummet by an alarming 89.09% over the past year. Investors have been wary as the company grapples with the challenges that have beset the biotech industry, including increased regulatory scrutiny and a shift in market sentiment away from high-risk sectors. The company’s financial health score of 1.4 is rated as ’Weak’ by InvestingPro, though it maintains more cash than debt on its balance sheet. The 52-week low marks a critical juncture for Eleven Biotherapeutics as it navigates through these headwinds in hopes of a turnaround. (Discover 10+ additional exclusive insights and real-time metrics with InvestingPro.)
In other recent news, Carisma Therapeutics has received a notice from the Nasdaq Stock Market regarding non-compliance with the exchange’s minimum bid price requirement. The company’s stock has closed below the $1.00 minimum bid price for 38 consecutive business days, prompting the notice. Under Nasdaq Listing Rule 5450(a)(1), Carisma Therapeutics now has a 180-day period, ending on July 7, 2025, to regain compliance by ensuring its stock price reaches or exceeds $1.00 per share for at least ten consecutive business days. If the company fails to meet this requirement by the deadline, it may qualify for an additional 180-day extension by transferring its listing to The Nasdaq Capital Market. During this period, Carisma Therapeutics must satisfy all other initial listing standards of that market, except for the minimum bid price. The company is considering a reverse stock split as a potential solution to address the bid price deficiency. Carisma Therapeutics has expressed its intention to monitor its stock’s closing bid price closely and evaluate possible solutions to comply with Nasdaq’s requirements. The company acknowledges that there is no guarantee of regaining compliance or meeting other Nasdaq standards to avoid delisting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.